Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

GSK's new chairman Hampton to take charge in May

Published 26/02/2015, 16:56
© Reuters. The signage for the GlaxoSmithKline building is pictured in London
NWG
-
NOVN
-
VOD
-
GSK
-

By Ben Hirschler

LONDON (Reuters) - GlaxoSmithKline (L:GSK) said on Thursday that its chairman-designate Philip Hampton would take charge of Britain's biggest drugmaker from May 7, an earlier transition than initially anticipated.

Hampton, who chairs Royal Bank of Scotland (L:RBS), was named as the pharmaceutical company's next chairman last September, but GSK said at the time he might not take up the position until Sept. 1, 2015, if he could not be released from other commitments.

In the event, Hampton is now able to take over with effect from the drugmaker's next annual meeting, following the appointment of Howard Davies as his successor at RBS.

Hampton is taking over at a testing time. GSK was hit last year by a record fine of nearly $500 million in China for bribing doctors and has disappointed investors with weak sales of its core respiratory drugs.

The poor performance was reflected in a big cut in the bonus paid to Chief Executive Andrew Witty, according to the company's annual report released on Thursday. Witty was awarded a bonus of 917,000 pounds for 2014, a reduction of 51 percent compared to 2013.

GSK is hoping that a $20 billion-plus asset swap with Novartis (VX:NOVN), which is due to close next week, will help revive its fortunes, although the deal promises a long-term path to more sustainable growth rather than any short-term fix.

Hampton will replace Chris Gent, who has chaired GSK since 2005, having previously led mobile phone company Vodafone (L:VOD) during a period of rapid growth.

Some analysts believe Hampton could usher in a period of significant change at GSK. Witty has already suggested that the company could consider spinning off some component units.

Hampton has been chairman of RBS since 2009, when he was parachuted in to help rescue the bank following its 45 billion- pound bailout during the financial crisis.

He has led RBS through a turbulent period during which it shed assets worth 1 trillion pounds to rid itself of toxic loans.

Hampton joined GSK's board on Jan. 1 and will become deputy chairman of the group on April 1.

© Reuters. The signage for the GlaxoSmithKline building is pictured in London

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.